New insight in pathogenesis of podocyte disfunction in minimal change disease.
- Author:
Shanshan LIU
1
;
Jianghua CHEN
2
Author Information
1. Kidney Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
2. Kidney Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. chenjianghua@zju.edu.cn.
- Publication Type:Journal Article
- MeSH:
Angiopoietin-like 4 Protein;
Angiopoietins;
metabolism;
Animals;
B7-1 Antigen;
metabolism;
Disease Models, Animal;
Humans;
Intracellular Signaling Peptides and Proteins;
metabolism;
Kidney;
pathology;
Membrane Proteins;
metabolism;
Mice;
Microfilament Proteins;
metabolism;
NF-kappa B;
metabolism;
Nephrosis, Lipoid;
pathology;
Podocytes;
pathology
- From:
Journal of Zhejiang University. Medical sciences
2016;45(2):214-218
- CountryChina
- Language:Chinese
-
Abstract:
Minimal change disease (MCD) is a common pathological type of nephrotic syndrome. Its main histology is the fusion of podocyte foot process. The pathogenesis of MCD is not clear, but previously it was thought to be related to immune mechanism. In recent years more studies show that podocyte injury is the key link in the pathogenesis of MCD. In MCD mouse model and human kidney tissues, the expressions of podocyte slit membrane protein-nephrin and podocin, skeleton protein-synaptopodin are decreased, and the expression of synaptopodin is correlated with the response to hormone therapy. In addition, newest studies focused on another two potocyte associated proteins, CD80 and Angiopoietin-like-4. CD80, a T cell stimulating molecule, is expressed in potocyte. Kappa B gene sequences can be activated by external microbes, antigens through acting potocytes, which can induce the upregulation of CD80 expression, cytoskeletal protein damage and the glomerular filtration rate changes, resulting in proteinuria. Angiopoietin-like-4 can be expressed in normal potocytes, but over-expression of angiopoietin-like-4 may injure the GBM charge barrier and induce the foot process fusion, leading to MCD. However, further studies on the factors inducing CD80 and Angiopoietin-like-4 expression, and the interaction between glomerular basement membrane and the two proteins are needed. Based on the mechanism of MCD, NF-kappa B inhibitors and sialylation therapy would be a novel non-immune therapy for MCD.
